Our upcoming forum next Thursday brings together four companies at exciting phases in their development. The management from e-Therapeutics (LON:ETX), Ergomed (LON:ERGO), Tissue Regenix (LON:TRX) and TekCapital (LON:TEK) will be updating investors on current developments and future prospects.
To ensure you don't miss out on the event on September 17, secure your place HERE.
First up is ServicePower Technologies, a company which deals, among other things, in the outsourcing and hosting of dispatch, claims & warranty processing and the implementation of scheduling software.
The shares have risen by almost 50% since the middle of July and chief executive Marne Martin will be at the forum to explain how the company intends to build on this momentum.
Next we have TekCapital, a global university technology company founded in Oxford. Its primary objective is to bring university innovations to the market place.
Among other projects, the company currently owns a patent on a breathalyser which measures the level of glucose in breath - a device which management believes could soon become the monitoring technique of choice for professionals in hospitals, clinics, doctor's offices and schools.
Chairman Clifford Gross will be on hand to update investors on the latest developments at TekCapital.
Meanwhile, Ergomed is focused on the provision of specialised services to the pharmaceutical industry and the development of new drugs.
The life sciences group recently announced that a cancer drug that it helped develop will undergo a second round efficacy and safety assessment in October - a significant milestone on a drug which has already been tested on 500 people.
Shares have been on an upwards trajectory since the beginning of 2015 and finance director Neil Clark will be present to explain what will be driving the share price over the medium to long term.
Finally, Tissue Regenix is a pioneering international medical technology company, leading the development of regenerative products to make replacement body parts using biological materials.
In July the company revealed that it had agreed an additional regional distribution agreement in the US for its skin graft product DermaPure. The product now has coverage in 30 US states including both its direct and indirect sales channels.
Chief Executive Antony Odell will be here to update investors on what has been happening at Tissue Regenix since he last presented with us back in May.
Please join us at 5:45pm to allow for a prompt 6pm start. Each company has 20 minutes to give a short presentation and then 10 minutes Q&A. This will be followed by the 'Champagne Raffle' where six guests will win a bottle each. The event will be rounded off with a drinks reception with canapés.